Related Experiment Video

Updated: Nov 8, 2025

Characterization of Cell Membrane Extensions and Studying Their Roles in Cancer Cell Adhesion Dynamics
08:11

Characterization of Cell Membrane Extensions and Studying Their Roles in Cancer Cell Adhesion Dynamics

Published on: March 26, 2018

8.5K

Exploiting D2 receptor β-arrestin2-biased signalling to suppress tumour growth of pituitary adenomas

Zhoubin Tan1, Zhuowei Lei2, Zisheng Yan1

  • 1Sino-German Neuro-Oncology Molecular Laboratory, Department of Neurosurgery, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.

British Journal of Pharmacology
|April 27, 2021
PubMed
Abstract

Insights

Beta-arrestin2 signaling, not G protein pathways, suppresses pituitary tumor growth. A novel D2 receptor agonist shows promise for treating pituitary tumors with enhanced selectivity.

Area of Science:

  • Endocrinology
  • Molecular Pharmacology
  • Oncology

Background:

  • Dopamine D2 receptor agonists are established treatments for pituitary adenomas.
  • The precise molecular mechanism of D2 receptor-mediated tumor suppression remains unclear, with limited evidence for canonical G protein signaling.

Purpose of the Study:

  • To investigate the role of beta-arrestin2-dependent signaling in mediating the inhibitory effects of D2 receptor agonists on pituitary tumor growth.
  • To compare the efficacy of beta-arrestin2-biased agonists versus G protein-biased agonists in preclinical models of pituitary tumors.

Main Methods:

  • Assessed G protein and beta-arrestin2 involvement in bromocriptine's growth suppression in rat pituitary tumor cell lines (MMQ, GH3).
  • Evaluated a beta-arrestin2-biased agonist (UNC9994) in vitro, in vivo (tumor-bearing mice), and in primary human pituitary adenomas.
  • Analyzed G protein signaling effects using a G protein-biased agonist (MLS1547) and a Gbeta gamma inhibitor (gallein).

Main Results:

  • Beta-arrestin2 signaling, not G protein pathways, mediated bromocriptine's pituitary tumor growth suppression.
  • The beta-arrestin2-biased agonist UNC9994 inhibited pituitary tumor cell growth both in vitro and in vivo.
  • UNC9994's anti-tumor effect involved inducing reactive oxygen species via downregulation of mitochondrial complex I subunit NDUFA1.
  • G protein signaling effects on tumor growth were cell-type-dependent.

Conclusions:

  • Beta-arrestin2-biased D2 receptor ligands represent a potentially more effective and selective therapeutic strategy for pituitary tumors compared to traditional G protein-biased agonists.
  • Low expression of G alpha i/o proteins and complex G protein signaling responses in pituitary tumors support the development of beta-arrestin2-biased therapies.
Keywords:
D2 receptorUNC9994functional selectivitypituitary adenomaβ-arrestin2

More Related Videos

Endoscopic Endonasal Trans-sphenoidal Approach: Minimally Invasive Surgery for Pituitary Adenomas07:43

Endoscopic Endonasal Trans-sphenoidal Approach: Minimally Invasive Surgery for Pituitary Adenomas

Published on: January 17, 2018

19.1K
Two-dimensional Gel Electrophoresis Coupled with Mass Spectrometry Methods for an Analysis of Human Pituitary Adenoma Tissue Proteome12:34

Two-dimensional Gel Electrophoresis Coupled with Mass Spectrometry Methods for an Analysis of Human Pituitary Adenoma Tissue Proteome

Published on: April 2, 2018

13.7K

Related Concept Videos

Receptor Downregulation in MVBs01:15

Receptor Downregulation in MVBs

Multivesicular bodies (MVBs) are mature endosomes that sort ubiquitinated proteins and then fuse with lysosomes to degrade the sorted proteins. Epidermal growth factor (EGF) and its receptor (EGFR) form a complex that can be internalized through endocytosis, sorted into an MVB, and later degraded.
The EGFR can initiate signaling pathways that  lead to cell proliferation, migration, and differentiation. Overexpression of EGFR  stimulates cells to proliferate. Excessive  EGFR...
2.4K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
5.2K
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.8K
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
3.3K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
4.0K
Amplifying Signals via Enzymatic Cascade01:22

Amplifying Signals via Enzymatic Cascade

When a ligand binds to a cell-surface receptor, the receptor's intracellular domain changes shape, which may either activate its enzyme function or allow its binding to other molecules. The initial signal is amplified by most signal transduction pathways. This means that a single ligand molecule can activate multiple molecules of a downstream target. Proteins that relay a signal are most commonly phosphorylated at one or more sites, activating or inactivating the protein. Kinases catalyze...
14.9K